Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus chemotherapy in pediatric relapsed/refractory acute leukemia
NL-OMON55833Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (3 cohorts), sponsored by Sanofi. Primary endpoints: Complete response rate in AML cohort, Complete response rate in B-ALL cohort and 1 more. Started Aug 2021; status: completed.
02
Drugs
isatuximab
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON55833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55833.